Back to Search Start Over

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

Authors :
Murray CJ
Barber RM
Foreman KJ
Abbasoglu Ozgoren A
Abd-Allah F
Abera SF
Aboyans V
Abraham JP
Abubakar I
Abu-Raddad LJ
Abu-Rmeileh NM
Achoki T
Ackerman IN
Ademi Z
Adou AK
Adsuar JC
Afshin A
Agardh EE
Alam SS
Alasfoor D
Albittar MI
Alegretti MA
Alemu ZA
Alfonso-Cristancho R
Alhabib S
Ali R
Alla F
Allebeck P
Almazroa MA
Alsharif U
Alvarez E
Alvis-Guzman N
Amare AT
Ameh EA
Amini H
Ammar W
Anderson HR
Anderson BO
Antonio CA
Anwari P
Arnlöv J
Arsic Arsenijevic VS
Artaman A
Asghar RJ
Assadi R
Atkins LS
Avila MA
Awuah B
Bachman VF
Badawi A
Bahit MC
Balakrishnan K
Banerjee A
Barker-Collo SL
Barquera S
Barregard L
Barrero LH
Basu A
Basu S
Basulaiman MO
Beardsley J
Bedi N
Beghi E
Bekele T
Bell ML
Benjet C
Bennett DA
Bensenor IM
Benzian H
Bernabé E
Bertozzi-Villa A
Beyene TJ
Bhala N
Bhalla A
Bhutta ZA
Bienhoff K
Bikbov B
Biryukov S
Blore JD
Blosser CD
Blyth FM
Bohensky MA
Bolliger IW
Bora Başara B
Bornstein NM
Bose D
Boufous S
Bourne RR
Boyers LN
Brainin M
Brayne CE
Brazinova A
Breitborde NJ
Brenner H
Briggs AD
Brooks PM
Brown JC
Brugha TS
Buchbinder R
Buckle GC
Budke CM
Bulchis A
Bulloch AG
Campos-Nonato IR
Carabin H
Carapetis JR
Cárdenas R
Carpenter DO
Caso V
Castañeda-Orjuela CA
Castro RE
Catalá-López F
Cavalleri F
Çavlin A
Chadha VK
Chang JC
Charlson FJ
Chen H
Chen W
Chiang PP
Chimed-Ochir O
Chowdhury R
Christensen H
Christophi CA
Cirillo M
Coates MM
Coffeng LE
Coggeshall MS
Colistro V
Colquhoun SM
Cooke GS
Cooper C
Cooper LT
Coppola LM
Cortinovis M
Criqui MH
Crump JA
Cuevas-Nasu L
Danawi H
Dandona L
Dandona R
Dansereau E
Dargan PI
Davey G
Davis A
Davitoiu DV
Dayama A
De Leo D
Degenhardt L
Del Pozo-Cruz B
Dellavalle RP
Deribe K
Derrett S
Des Jarlais DC
Dessalegn M
Dharmaratne SD
Dherani MK
Diaz-Torné C
Dicker D
Ding EL
Dokova K
Dorsey ER
Driscoll TR
Duan L
Duber HC
Ebel BE
Edmond KM
Elshrek YM
Endres M
Ermakov SP
Erskine HE
Eshrati B
Esteghamati A
Estep K
Faraon EJ
Farzadfar F
Fay DF
Feigin VL
Felson DT
Fereshtehnejad SM
Fernandes JG
Ferrari AJ
Fitzmaurice C
Flaxman AD
Fleming TD
Foigt N
Forouzanfar MH
Fowkes FG
Paleo UF
Franklin RC
Fürst T
Gabbe B
Gaffikin L
Gankpé FG
Geleijnse JM
Gessner BD
Gething P
Gibney KB
Giroud M
Giussani G
Gomez Dantes H
Gona P
González-Medina D
Gosselin RA
Gotay CC
Goto A
Gouda HN
Graetz N
Gugnani HC
Gupta R
Gupta R
Gutiérrez RA
Haagsma J
Hafezi-Nejad N
Hagan H
Halasa YA
Hamadeh RR
Hamavid H
Hammami M
Hancock J
Hankey GJ
Hansen GM
Hao Y
Harb HL
Haro JM
Havmoeller R
Hay SI
Hay RJ
Heredia-Pi IB
Heuton KR
Heydarpour P
Higashi H
Hijar M
Hoek HW
Hoffman HJ
Hosgood HD
Hossain M
Hotez PJ
Hoy DG
Hsairi M
Hu G
Huang C
Huang JJ
Husseini A
Huynh C
Iannarone ML
Iburg KM
Innos K
Inoue M
Islami F
Jacobsen KH
Jarvis DL
Jassal SK
Jee SH
Jeemon P
Jensen PN
Jha V
Jiang G
Jiang Y
Jonas JB
Juel K
Kan H
Karch A
Karema CK
Karimkhani C
Karthikeyan G
Kassebaum NJ
Kaul A
Kawakami N
Kazanjan K
Kemp AH
Kengne AP
Keren A
Khader YS
Khalifa SE
Khan EA
Khan G
Khang YH
Kieling C
Kim D
Kim S
Kim Y
Kinfu Y
Kinge JM
Kivipelto M
Knibbs LD
Knudsen AK
Kokubo Y
Kosen S
Krishnaswami S
Kuate Defo B
Kucuk Bicer B
Kuipers EJ
Kulkarni C
Kulkarni VS
Kumar GA
Kyu HH
Lai T
Lalloo R
Lallukka T
Lam H
Lan Q
Lansingh VC
Larsson A
Lawrynowicz AE
Leasher JL
Leigh J
Leung R
Levitz CE
Li B
Li Y
Li Y
Lim SS
Lind M
Lipshultz SE
Liu S
Liu Y
Lloyd BK
Lofgren KT
Logroscino G
Looker KJ
Lortet-Tieulent J
Lotufo PA
Lozano R
Lucas RM
Lunevicius R
Lyons RA
Ma S
Macintyre MF
Mackay MT
Majdan M
Malekzadeh R
Marcenes W
Margolis DJ
Margono C
Marzan MB
Masci JR
Mashal MT
Matzopoulos R
Mayosi BM
Mazorodze TT
Mcgill NW
Mcgrath JJ
Mckee M
Mclain A
Meaney PA
Medina C
Mehndiratta MM
Mekonnen W
Melaku YA
Meltzer M
Memish ZA
Mensah GA
Meretoja A
Mhimbira FA
Micha R
Miller TR
Mills EJ
Mitchell PB
Mock CN
Mohamed Ibrahim N
Mohammad KA
Mokdad AH
Mola GL
Monasta L
Montañez Hernandez JC
Montico M
Montine TJ
Mooney MD
Moore AR
Moradi-Lakeh M
Moran AE
Mori R
Moschandreas J
Moturi WN
Moyer ML
Mozaffarian D
Msemburi WT
Mueller UO
Mukaigawara M
Mullany EC
Murdoch ME
Murray J
Murthy KS
Naghavi M
Naheed A
Naidoo KS
Naldi L
Nand D
Nangia V
Narayan KM
Nejjari C
Neupane SP
Newton CR
Ng M
Ngalesoni FN
Nguyen G
Nisar MI
Nolte S
Norheim OF
Norman RE
Norrving B
Nyakarahuka L
Oh IH
Ohkubo T
Ohno SL
Olusanya BO
Opio JN
Ortblad K
Ortiz A
Pain AW
Pandian JD
Panelo CI
Papachristou C
Park EK
Park JH
Patten SB
Patton GC
Paul VK
Pavlin BI
Pearce N
Pereira DM
Perez-Padilla R
Perez-Ruiz F
Perico N
Pervaiz A
Pesudovs K
Peterson CB
Petzold M
Phillips MR
Phillips BK
Phillips DE
Piel FB
Plass D
Poenaru D
Polinder S
Pope D
Popova S
Poulton RG
Pourmalek F
Prabhakaran D
Prasad NM
Pullan RL
Qato DM
Quistberg DA
Rafay A
Rahimi K
Rahman SU
Raju M
Rana SM
Razavi H
Reddy KS
Refaat A
Remuzzi G
Resnikoff S
Ribeiro AL
Richardson L
Richardus JH
Roberts DA
Rojas-Rueda D
Ronfani L
Roth GA
Rothenbacher D
Rothstein DH
Rowley JT
Roy N
Ruhago GM
Saeedi MY
Saha S
Sahraian MA
Sampson UK
Sanabria JR
Sandar L
Santos IS
Satpathy M
Sawhney M
Scarborough P
Schneider IJ
Schöttker B
Schumacher AE
Schwebel DC
Scott JG
Seedat S
Sepanlou SG
Serina PT
Servan-Mori EE
Shackelford KA
Shaheen A
Shahraz S
Shamah Levy T
Shangguan S
She J
Sheikhbahaei S
Shi P
Shibuya K
Shinohara Y
Shiri R
Shishani K
Shiue I
Shrime MG
Sigfusdottir ID
Silberberg DH
Simard EP
Sindi S
Singh A
Singh JA
Singh L
Skirbekk V
Slepak EL
Sliwa K
Soneji S
Søreide K
Soshnikov S
Sposato LA
Sreeramareddy CT
Stanaway JD
Stathopoulou V
Stein DJ
Stein MB
Steiner C
Steiner TJ
Stevens A
Stewart A
Stovner LJ
Stroumpoulis K
Sunguya BF
Swaminathan S
Swaroop M
Sykes BL
Tabb KM
Takahashi K
Tandon N
Tanne D
Tanner M
Tavakkoli M
Taylor HR
Te Ao BJ
Tediosi F
Temesgen AM
Templin T
Ten Have M
Tenkorang EY
Terkawi AS
Thomson B
Thorne-Lyman AL
Thrift AG
Thurston GD
Tillmann T
Tonelli M
Topouzis F
Toyoshima H
Traebert J
Tran BX
Trillini M
Truelsen T
Tsilimbaris M
Tuzcu EM
Uchendu US
Ukwaja KN
Undurraga EA
Uzun SB
Van Brakel WH
Van De Vijver S
van Gool CH
Van Os J
Vasankari TJ
Venketasubramanian N
Violante FS
Vlassov VV
Vollset SE
Wagner GR
Wagner J
Waller SG
Wan X
Wang H
Wang J
Wang L
Warouw TS
Weichenthal S
Weiderpass E
Weintraub RG
Wenzhi W
Werdecker A
Westerman R
Whiteford HA
Wilkinson JD
Williams TN
Wolfe CD
Wolock TM
Woolf AD
Wulf S
Wurtz B
Xu G
Yan LL
Yano Y
Ye P
Yentür GK
Yip P
Yonemoto N
Yoon SJ
Younis MZ
Yu C
Zaki ME
Zhao Y
Zheng Y
Zonies D
Zou X
Salomon JA
Lopez AD
Vos T
Source :
Lancet (London, England) [Lancet] 2015 Nov 28; Vol. 386 (10009), pp. 2145-91. Date of Electronic Publication: 2015 Aug 28.
Publication Year :
2015

Abstract

Background: The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age-sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic development.<br />Methods: We used the published GBD 2013 data for age-specific mortality, years of life lost due to premature mortality (YLLs), and years lived with disability (YLDs) to calculate DALYs and HALE for 1990, 1995, 2000, 2005, 2010, and 2013 for 188 countries. We calculated HALE using the Sullivan method; 95% uncertainty intervals (UIs) represent uncertainty in age-specific death rates and YLDs per person for each country, age, sex, and year. We estimated DALYs for 306 causes for each country as the sum of YLLs and YLDs; 95% UIs represent uncertainty in YLL and YLD rates. We quantified patterns of the epidemiological transition with a composite indicator of sociodemographic status, which we constructed from income per person, average years of schooling after age 15 years, and the total fertility rate and mean age of the population. We applied hierarchical regression to DALY rates by cause across countries to decompose variance related to the sociodemographic status variable, country, and time.<br />Findings: Worldwide, from 1990 to 2013, life expectancy at birth rose by 6·2 years (95% UI 5·6-6·6), from 65·3 years (65·0-65·6) in 1990 to 71·5 years (71·0-71·9) in 2013, HALE at birth rose by 5·4 years (4·9-5·8), from 56·9 years (54·5-59·1) to 62·3 years (59·7-64·8), total DALYs fell by 3·6% (0·3-7·4), and age-standardised DALY rates per 100 000 people fell by 26·7% (24·6-29·1). For communicable, maternal, neonatal, and nutritional disorders, global DALY numbers, crude rates, and age-standardised rates have all declined between 1990 and 2013, whereas for non-communicable diseases, global DALYs have been increasing, DALY rates have remained nearly constant, and age-standardised DALY rates declined during the same period. From 2005 to 2013, the number of DALYs increased for most specific non-communicable diseases, including cardiovascular diseases and neoplasms, in addition to dengue, food-borne trematodes, and leishmaniasis; DALYs decreased for nearly all other causes. By 2013, the five leading causes of DALYs were ischaemic heart disease, lower respiratory infections, cerebrovascular disease, low back and neck pain, and road injuries. Sociodemographic status explained more than 50% of the variance between countries and over time for diarrhoea, lower respiratory infections, and other common infectious diseases; maternal disorders; neonatal disorders; nutritional deficiencies; other communicable, maternal, neonatal, and nutritional diseases; musculoskeletal disorders; and other non-communicable diseases. However, sociodemographic status explained less than 10% of the variance in DALY rates for cardiovascular diseases; chronic respiratory diseases; cirrhosis; diabetes, urogenital, blood, and endocrine diseases; unintentional injuries; and self-harm and interpersonal violence. Predictably, increased sociodemographic status was associated with a shift in burden from YLLs to YLDs, driven by declines in YLLs and increases in YLDs from musculoskeletal disorders, neurological disorders, and mental and substance use disorders. In most country-specific estimates, the increase in life expectancy was greater than that in HALE. Leading causes of DALYs are highly variable across countries.<br />Interpretation: Global health is improving. Population growth and ageing have driven up numbers of DALYs, but crude rates have remained relatively constant, showing that progress in health does not mean fewer demands on health systems. The notion of an epidemiological transition--in which increasing sociodemographic status brings structured change in disease burden--is useful, but there is tremendous variation in burden of disease that is not associated with sociodemographic status. This further underscores the need for country-specific assessments of DALYs and HALE to appropriately inform health policy decisions and attendant actions.<br />Funding: Bill & Melinda Gates Foundation.<br /> (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1474-547X
Volume :
386
Issue :
10009
Database :
MEDLINE
Journal :
Lancet (London, England)
Publication Type :
Academic Journal
Accession number :
26321261
Full Text :
https://doi.org/10.1016/S0140-6736(15)61340-X